Sichenzia Ross Ference Kesner LLP Represents Immuron Limited on $6.1M IPO and NASDAQ listing
Press Release — New York, NY — June 14, 2017 — Sichenzia Ross Ference Kesner LLP (“SRFK”) announced today the Firm has represented Immuron Limited (NASDAQ: IMRN) (ASX : IMC), a clinical-stage biopharmaceutical company focused on NASH and OTC products, on the company’s U.S. underwritten public offering of American Depository Shares (ADSs) and warrants to purchase the company’s ADSs at a combined offering price of $10.00.
Each ADS represents 40 shares of the company’s ordinary shares. Immuron raised approximately $6,100,000 in gross proceeds, which will be used to advance their products, platform technologies, working capital, and general corporate purposes.
SRFK successfully advised the process by which Immuron listed its ADSs and warrants on NASDAQ under the symbols “NASDAQ:IMRN and IMRNW” respectively, which began trading on June 9, 2017.
The Sichenzia Ross Ference Kesner LLP team was led by Partners Gregory Sichenzia, Darrin M. Ocasio, and David Manno.
- Sichenzia Ross Ference LLP Represents BriaCell Therapeutics Corp. in Nasdaq listing and $25 Million Public Offering - February 26, 2021
- Sichenzia Ross Ference LLP Represents AmpliTech Group, Inc. in Nasdaq Uplisting and $11 Million Upsized Public Offering - February 25, 2021
- Sichenzia Ross Ference LLP Represents CloudCommerce, Inc. in $10.0 Million Registered Direct Offering - February 23, 2021